Evidence map›Paper›PMID 29602733›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2018

What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public.

Shana D Stites, Jonathan D Rubright, Jason Karlawish

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Effects of caregiving experience on expectations of becoming an Alzheimer's disease caregiver in the future.The journals of gerontology. Series B, Psychological sciences and social sciences · 2026
    Article
  7. Article
  8. "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Putting participants and study partners FIRST when clinical trials end early.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  18. Article
  19. Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Shana D StitesDepartment of Medical Ethics and Health Policy, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: stites@upenn.edu.
Jonathan D RubrightNational Board of Medical Examiners, Philadelphia, PA, USA.
Jason KarlawishPenn Memory Center, Department of Medicine, Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.

Funding

UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
Dissemination, Implementation, and Evaluation of Native STAND in AI CommunitiesU48DP005006 · DP · OREGON HEALTH & SCIENCE UNIVERSITY · PI BECKER, THOMAS MARK · 2014 to 2018
$6.3M
NCCDPHP CDC HHS U48 DP005006NIA NIH HHS P30 AG010124
6 · The paper itself

Abstract

introductionUnderstanding the prevalence of beliefs, attitudes, and expectations about Alzheimer's disease dementia in the public could inform strategies to mitigate stigma.

methodsRandom sample of 317 adults from the U.S. public was analyzed to understand reactions toward a man with mild-stage Alzheimer's disease dementia.

resultsIn adjusted analyses, over half of respondents expected the person to be discriminated against by employers (55.3%; 95% confidence interval [CI] = 47.0-65.2) and be excluded from medical decision-making (55.3%; 95% CI = 46.9-65.4). Almost half expected his health insurance would be limited based on data in the medical record (46.6%; 95% CI = 38.0-57.2), a brain imaging result (45.6%, 95% CI = 37.0-56.3), or genetic test result (44.7%; 95% CI = 36.0-55.4). DISCUSSION: Public education and policies are needed to address concerns about employment and insurance discrimination. Studies are needed to discover how advances in diagnosis and treatment may change Alzheimer's disease stigma.

Indexed as

AttitudeEmploymentSocial StigmaAdultAgedAlzheimer DiseaseDementiaDiscrimination, PsychologicalFemaleHumansInsurance, HealthMaleSurveys and QuestionnairesUnited StatesAlzheimer's diseaseGeneral publicPolicyProgram developmentStigma

Identifiers

PMID29602733
PMCPMC6050091

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.